20152014|2013|2012|2011201020092008
 
  2012年度

Kitagaki M., Isoda K., Kamada H., Kobayashi T., Tsunoda S., Tsutsumi Y., Niida T., Kujiraoka T., Ishigami N., Ishihara M., Matsubara O., Ohsuzu F., Kikuchi M.
Novel TNF-alpha receptor-1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice.
J. Atheroscler. Thromb., 19(1):36-46, 2012. [PubMed]


Nabeshi H., Yoshikawa T., Matsuyama K., Nakazato Y., Arimori A., Isobe M., Tochigi S., Kondoh S., Hirai T., Akase T., Yamashita T., Yamashita K., Yoshida T., Nagano K., Abe Y., Yoshioka Y., Kamada H., Imazawa T., Kondoh M., Yagi K., Mayumi T., Itoh N., Tsunoda S., Tsutsumi Y.
Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnol., 23:1-8, 2012. [PubMed]

Hirai T., Yoshikawa T., Nabeshi H., Yoshida T., Tochigi S., Ichihashi K., Uji M., Akase T., Nagano K., Abe Y., Kamada H., Tsunoda S., Yoshioka Y.,Itoh N., Tsutsumi Y.
Amorphous silica nanoparticles size-dependently aggravate atopic dermatitis-like skin lesions following an intradermal injection.
Part. Fibre. Toxicol., 9(1):3, 2012. [PubMed]

Yamashita T., Okamura T., Nagano K., Imai S., Abe Y., Nabeshi H., Yoshikawa T., Yoshioka Y., Kamada H., Tsutsumi Y., Tsunoda S.
Rho GDP-dissociation inhibitor alpha is associated with cancer metastasis in colon and prostate cancer.
Pharmazie., 67(3): 253-255, 2012. [PubMed]

Yamashita T., Nagano K., Kanasaki S., Maeda Y., Furuya T., Inoue M., Nabeshi H., Yoshikawa T., Yoshioka Y., Itoh N., Abe Y., Kamada H., Tsutsumi Y., Tsunoda S.
Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells.
Biochem. Biophys. Res. Commun., 421(1):140-4, 2012. [PubMed]

Morishita Y., Yoshioka Y., Satoh H., Nojiri N., Nagano K., Abe Y., Kamada H., Tsunoda S., Nabeshi H., Yoshikawa T., Tsutsumi Y.
Distribution and histological effects of intravenously administered amorphous nanosilica particles in the testes of mice.
Biochem. Biophys. Res. Commun., 420(2):297-301, 2012. [PubMed]

Morishige T., Yoshioka Y., Inakura H., Tanabe A., Narimatsu S., Yao X., Monobe Y., Imazawa T., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N., Nakagawa S.
Suppression of nanosilica particle–induced inflammation by surface modification of the particles.
Arch. Toxicol., 86(8):1297-307, 2012. [PubMed]

Hirai T., Yoshikawa T., Nabeshi H., Yoshida T., Tochigi S., Uji M., Ichihashi K., Akase T., Nagano K., Abe Y., Kamada H., Tsunoda S., Yoshioka Y., Itoh N., Tsutsumi Y.
Dermal absorption of amorphous nanosilica particles after topical exposure for three days.
Pharmazie., 67(8):742-3, 2012. [PubMed]

Yoshida T., Matsuyama K., Yoshikawa T., Nabeshi H., Nakazato Y., Tochigi S., Hirai T., Uji M., Ichihashi K., Akase T., Nagano K., Abe Y., Kamada H., Tsunoda S., Yoshioka Y., Itoh N., Tsutsumi Y.
Amorphous nanosilica particles induce ROS generation in Langerhans cells.
Pharmazie., 67(8):740-1, 2012. [PubMed]

Nagano T., Yoshioka Y., Higashisaka K., Kunieda A., Hata K., Nagano K., Abe Y., Kamada H., Tsunoda S., Nabeshi H., Yoshikawa T., Tsutsumi Y.
Potential of acute-phase proteins as biomarkers for sub-nano platinum exposure.
Pharmazie., 67(11):958-9, 2012.[PubMed]

Hirai T., Yoshioka Y., Takahashi H., Ichihashi K., Yoshida T., Tochigi S., Nagano K., Abe Y., Kamada H., Tsunoda S., Nabeshi H., Yoshikawa T., Tsutsumi Y.
Amorphous silica nanoparticles enhance cross-presentation in murine dendritic cells.
Biochem. Biophys. Res. Commun., 427(3):553-6, 2012. [PubMed]

Higashisaka K., Yoshioka Y., Yamashita K., Morishita Y., Pan H., Ogura T., Nagano T., Kunieda A., Nagano K., Abe Y., Kamada H., Tsunoda S., Nabeshi H., Yoshikawa T., Tsutsumi Y.
Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles.
Nanoscale Res. Lett., 7(1):555, 2012. [PubMed]

Yoshida T., Yoshioka Y., Matsuyama K., Nakazato Y., Tochigi S., Hirai T., Kondoh S., Nagano K., Abe Y., Kamada H., Tsunoda S., Nabeshi H., Yoshikawa T., Tsutsumi Y.
Surface modification of amorphous nanosilica particles suppresses nanosilica-induced cytotoxicity, ROS generation, and DNA damage in various mammalian cells.
Biochem. Biophys. Res. Commun., 427(4):748-52, 2012. [PubMed]

Nagano K., Okamura T., Yamashita T., Kanasaki S., Maeda Y., Inoue M., Abe Y., Kamada H., Tsutsumi Y., Tsunoda S.
Expression of Rho GDP dissociation inhibitor correlates positively with lymph node metastasis in colorectal cancer.
Eur. J. Cancer., 48(5): S64, 2012. (Supplement)

Kamada H., Yamashita T., Kanasaki S., Maeda Y., Inoue M., Nagano K., Abe Y., Tsutsumi Y., Tsunoda S.
Detection of drug-target proteins on tumor-derived exosomes by ELISA using anti-CD81 antibodies.
Eur. J. Cancer., 48(5): S238, 2012. (Supplement).

Yamashita T., Yamashita K., Nabeshi H., Yoshikawa T., Yoshioka Y., Tsunoda S., Tsutsumi Y.
Carbone nanonmaterials: efficacy and safety for nanomedicine.
Materials., 5(2): 350-363, 2012.

堤 康央,角田慎一
ドラッグデリバリーシステム(DDS)技術の開発.
新しい薬学事典., 朝倉書店,pp.51-54, 2012.

Yamashita K., Yoshioka Y.
The safety assessment of nanomaterials in reproductive developmental field.
Yakugaku Zasshi., 132(3):331-5, 2012. [PubMed]

Yoshida T., Yoshikawa T., Nabeshi H., Tsutsumi Y.
Relation analysis between intracellular distribution of nanomateriarls, ROS generation and DNA damage.
Yakugaku Zasshi., 132(3):295-300, 2012. [PubMed]

平井敏郎, 吉岡靖雄, 堤 康央
ナノカーボンDDSの可能性と安全性.
『ドラッグデリバリーシステムの新展開Ⅱ -核酸医薬・抗体医薬・ワクチン医療を支えるDDS技術-』., シーエムシー出版, pp.242-7, 2012.

鎌田春彦, 堤 康央, 角田慎一
抗体プロテオミクス技術.
『臨床プロテオーム ~個別医療を目指す臨床バイオマーカー探索~』., 金原出版株式会社, pp.153-60, 2012.

永野貴士, 堤 康央, 吉岡靖雄
安全なナノマテリアルの開発に資するナノ安全科学研究の最前線.
感染炎症免疫., 42(3):72-4, 2012.

吉岡靖雄, 堤 康央
ナノ安全科学研究の最前線.
CICSJ Bulletin., pp. 50-52, 2012.


Copyright (C) 2009 Osaka Univ. Dept. Toxicology All rights reserved.